Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming December 2018
Attention-deficit-hyperactivity disorder (ADHD) affects over 40 million people—children, adolescents, and adults—across the major pharmaceutical markets. The key treatment goals for both pediatric and adult ADHD include controlling the core symptoms of the condition—inattention and/or hyperactivity/impulsivity—as well improving patients’ overall functioning and quality of life. Psychostimulants are the predominant drug class prescribed for both pediatric and adult ADHD, though nonstimulant therapies serve as alternative or later-line options. Shortcomings in existing therapies, however, represent potential areas of opportunity for emerging therapies to be differentiated from competitors. Furthermore, recognition and diagnosis of adult ADHD continues to grow, particularly in the United States, but this population remains underdetected and undertreated, representing a sizable market opportunity.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, EU5, Japan
Primary research: 17 country-specific interviews with thought-leading psychiatrists and ADHD experts
Supported by survey data collected for this and other DRG research
Epidemiology: Prevalence of ADHD by country, segmented by pediatric and adult ADHD
Forecast: 10-year, annualized, drug-level sales and patient share of key ADHD therapies through 2027, segmented by brands/generics and pediatric/adult ADHD.
Emerging therapies: Phase III/PR: 5 drugs. Phase II: 4 drugs. Coverage of select preclinical and Phase I products.